ANCC PMHNP Exam
Questions and Ansẉers with
rationales 2026\2027 update
This Exam contains:
Guarantee passing score
Questions and Ansẉers
format set of multiple-choice
Expert-Verified rationales
Verified ẉith trusted textbooks
,───────────────────────────────────────────────────────
─
Question 1: What is the FDA black box warning associated with the
use of SSRIs in children, adolescents, and young adults up to age
24?
Answer: Increased risk of suicidal thinking and behavior (suicidality).
Rationale: All antidepressants carry an FDA black box warning
regarding increased suicidality in pediatric and young adult
populations. The PMHNP must monitor these patients closely,
especially during the first 1 to 2 months of therapy or during
dosage changes, as energy levels may improve before mood
improves, potentially increasing the risk of acting on suicidal
thoughts.
Question 2: What hematological parameter must be monitored
weekly for the first 6 months when prescribing clozapine?
Answer: Absolute Neutrophil Count (ANC).
Rationale: Clozapine carries a risk of severe, potentially fatal
agranulocytosis. Through the REMS (Risk Evaluation and Mitigation
Strategy) program, the ANC must be monitored weekly for the first 6
months, every 2 weeks for the next 6 months, and monthly
thereafter if counts remain stable.
Question 3: How do the clinical presentations of Neuroleptic
Malignant Syndrome (NMS) and Serotonin Syndrome differ regarding
muscle tone and temperature?
Answer: NMS presents with "lead pipe" muscle rigidity and profound
hyperthermia, whereas Serotonin Syndrome presents with
hyperreflexia, clonus (often lower extremities), and milder
hyperthermia.
Rationale: Differentiating these two conditions is critical. NMS is an
idiosyncratic reaction to antipsychotics (dopamine antagonism)
,characterized by extreme rigidity. Serotonin syndrome is caused by
excessive serotonergic activity and is characterized by
neuromuscular hyperactivity (clonus, hyperreflexia).
Question 4: At what serum lithium level do signs of severe lithium
toxicity typically begin to appear?
Answer: > 2.0 mEq/L.
Rationale: While therapeutic levels are typically 0.6 to 1.2 mEq/L,
severe toxicity (characterized by gross tremor, ataxia, confusion,
seizures, and arrhythmias) usually occurs at levels exceeding 2.0
mEq/L. Treatment involves stopping the drug, IV fluids, and
potentially hemodialysis.
Question 5: What dietary restrictions are strictly required for a
patient prescribed a Monoamine Oxidase Inhibitor (MAOI)?
Answer: A tyramine-restricted diet.
Rationale: MAOIs inhibit the breakdown of tyramine. Consuming
tyramine-rich foods (aged cheeses, cured meats, fermented soy
products, certain beers) can lead to a hypertensive crisis,
characterized by severe headache, nausea, and potentially stroke or
death.
Question 6: What is the required washout period when switching a
patient from Fluoxetine to an MAOI?
Answer: At least 5 weeks.
Rationale: Fluoxetine has a very long half-life (up to 7 days for its
active metabolite, norfluoxetine). To prevent serotonin syndrome, a
minimum 5-week washout period is required after stopping
fluoxetine before initiating an MAOI. For other SSRIs/SNRIs, the
washout period is typically 2 weeks.
Question 7: What severe, potentially life-threatening dermatological
adverse effect is associated with lamotrigine, and how can the risk
be mitigated?
, Answer: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN). The risk is mitigated by slow titration of the dose.
Rationale: Lamotrigine carries a black box warning for serious skin
rashes. The risk is significantly reduced by starting at a low dose
and titrating slowly (e.g., increasing by no more than 50-100 mg
every 1-2 weeks). If any rash appears, the drug must be
discontinued immediately.
Question 8: What are the two primary FDA-approved indications for
prescribing bupropion, and what is a major contraindication for its
use?
Answer: Major Depressive Disorder (MDD) and smoking cessation
(under the brand name Zyban). A major contraindication is a seizure
disorder or eating disorder (due to lowered seizure threshold).
Rationale: Bupropion is a norepinephrine-dopamine reuptake
inhibitor (NDRI). It lowers the seizure threshold, making it
contraindicated in patients with epilepsy, anorexia, or bulimia
nervosa.
Question 9: What is the first-line pharmacological treatment for
Tardive Dyskinesia (TD)?
Answer: Vesicular monoamine transporter 2 (VMAT2) inhibitors,
such as valbenazine or deutetrabenazine.
Rationale: VMAT2 inhibitors are the only FDA-approved medications
specifically indicated for TD. They work by depleting presynaptic
dopamine, thereby reducing the involuntary movements associated
with chronic antipsychotic use.
Question 10: What is the first-line pharmacological treatment for a
patient experiencing acute antipsychotic-induced acute dystonia?
Answer: Intramuscular or intravenous diphenhydramine (Benadryl)
or benztropine (Cogentin).
Rationale: Acute dystonia is an extrapyramidal symptom (EPS)
caused by dopamine blockade. Anticholinergic medications like
Questions and Ansẉers with
rationales 2026\2027 update
This Exam contains:
Guarantee passing score
Questions and Ansẉers
format set of multiple-choice
Expert-Verified rationales
Verified ẉith trusted textbooks
,───────────────────────────────────────────────────────
─
Question 1: What is the FDA black box warning associated with the
use of SSRIs in children, adolescents, and young adults up to age
24?
Answer: Increased risk of suicidal thinking and behavior (suicidality).
Rationale: All antidepressants carry an FDA black box warning
regarding increased suicidality in pediatric and young adult
populations. The PMHNP must monitor these patients closely,
especially during the first 1 to 2 months of therapy or during
dosage changes, as energy levels may improve before mood
improves, potentially increasing the risk of acting on suicidal
thoughts.
Question 2: What hematological parameter must be monitored
weekly for the first 6 months when prescribing clozapine?
Answer: Absolute Neutrophil Count (ANC).
Rationale: Clozapine carries a risk of severe, potentially fatal
agranulocytosis. Through the REMS (Risk Evaluation and Mitigation
Strategy) program, the ANC must be monitored weekly for the first 6
months, every 2 weeks for the next 6 months, and monthly
thereafter if counts remain stable.
Question 3: How do the clinical presentations of Neuroleptic
Malignant Syndrome (NMS) and Serotonin Syndrome differ regarding
muscle tone and temperature?
Answer: NMS presents with "lead pipe" muscle rigidity and profound
hyperthermia, whereas Serotonin Syndrome presents with
hyperreflexia, clonus (often lower extremities), and milder
hyperthermia.
Rationale: Differentiating these two conditions is critical. NMS is an
idiosyncratic reaction to antipsychotics (dopamine antagonism)
,characterized by extreme rigidity. Serotonin syndrome is caused by
excessive serotonergic activity and is characterized by
neuromuscular hyperactivity (clonus, hyperreflexia).
Question 4: At what serum lithium level do signs of severe lithium
toxicity typically begin to appear?
Answer: > 2.0 mEq/L.
Rationale: While therapeutic levels are typically 0.6 to 1.2 mEq/L,
severe toxicity (characterized by gross tremor, ataxia, confusion,
seizures, and arrhythmias) usually occurs at levels exceeding 2.0
mEq/L. Treatment involves stopping the drug, IV fluids, and
potentially hemodialysis.
Question 5: What dietary restrictions are strictly required for a
patient prescribed a Monoamine Oxidase Inhibitor (MAOI)?
Answer: A tyramine-restricted diet.
Rationale: MAOIs inhibit the breakdown of tyramine. Consuming
tyramine-rich foods (aged cheeses, cured meats, fermented soy
products, certain beers) can lead to a hypertensive crisis,
characterized by severe headache, nausea, and potentially stroke or
death.
Question 6: What is the required washout period when switching a
patient from Fluoxetine to an MAOI?
Answer: At least 5 weeks.
Rationale: Fluoxetine has a very long half-life (up to 7 days for its
active metabolite, norfluoxetine). To prevent serotonin syndrome, a
minimum 5-week washout period is required after stopping
fluoxetine before initiating an MAOI. For other SSRIs/SNRIs, the
washout period is typically 2 weeks.
Question 7: What severe, potentially life-threatening dermatological
adverse effect is associated with lamotrigine, and how can the risk
be mitigated?
, Answer: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN). The risk is mitigated by slow titration of the dose.
Rationale: Lamotrigine carries a black box warning for serious skin
rashes. The risk is significantly reduced by starting at a low dose
and titrating slowly (e.g., increasing by no more than 50-100 mg
every 1-2 weeks). If any rash appears, the drug must be
discontinued immediately.
Question 8: What are the two primary FDA-approved indications for
prescribing bupropion, and what is a major contraindication for its
use?
Answer: Major Depressive Disorder (MDD) and smoking cessation
(under the brand name Zyban). A major contraindication is a seizure
disorder or eating disorder (due to lowered seizure threshold).
Rationale: Bupropion is a norepinephrine-dopamine reuptake
inhibitor (NDRI). It lowers the seizure threshold, making it
contraindicated in patients with epilepsy, anorexia, or bulimia
nervosa.
Question 9: What is the first-line pharmacological treatment for
Tardive Dyskinesia (TD)?
Answer: Vesicular monoamine transporter 2 (VMAT2) inhibitors,
such as valbenazine or deutetrabenazine.
Rationale: VMAT2 inhibitors are the only FDA-approved medications
specifically indicated for TD. They work by depleting presynaptic
dopamine, thereby reducing the involuntary movements associated
with chronic antipsychotic use.
Question 10: What is the first-line pharmacological treatment for a
patient experiencing acute antipsychotic-induced acute dystonia?
Answer: Intramuscular or intravenous diphenhydramine (Benadryl)
or benztropine (Cogentin).
Rationale: Acute dystonia is an extrapyramidal symptom (EPS)
caused by dopamine blockade. Anticholinergic medications like
